EXPERT NOTES:
CONTEXT: EU, Commercial RWD Data Source
IMPACT: Access to EU RWD, drive cutting edge improvements in patient outcome
Time Taken = 3 mins
QUOTES FROM SOURCE:
1. “NEW YORK and LONDON, July 8, 2020 /PRNewswire/ — Today Aetion and Cegedim Health Data announced a new partnership to integrate Cegedim’s THIN® European real-world data (RWD) into Aetion Evidence Platform® (AEP).”
2. “AEP analyzes data from the real world, including claims, electronic health records, registries, and clinical trial data to produce transparent, rapid, and scientifically validated real-world evidence (RWE) on the safety, effectiveness, and value of medical interventions.”
3. “This new collaboration with Cegedim Health Data will enable Aetion’s clients, including top biopharma companies, leading payers, and regulatory agencies, to employ leading trans-Atlantic RWD to unlock essential insights about treatments.”
4. “Carolyn Magill, CEO, Aetion, comments: “Over the last few months, COVID-19 has changed the drug development landscape, as leading biopharma companies, regulators, and health technology assessment bodies (HTAs) alike look to real-world data to urgently answer questions on treatment utilization, safety, and effectiveness.”
5. “Cegedim Health Data provides Real World Data and Evidence (RWD-E) to drive cutting edge improvements in patient outcomes.”